These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 31742915)
1. Drug Policy in the Real World. Pullen LC Am J Transplant; 2019 Nov; 19(11):2963-2964. PubMed ID: 31742915 [No Abstract] [Full Text] [Related]
2. Regulating drugs for effectiveness and safety: a public health perspective. Zito JM; Socolar SJ; Eilers R; Crystal S; Lexchin J Med Care; 2007 Sep; 45(9):911. PubMed ID: 17712264 [No Abstract] [Full Text] [Related]
3. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015. MacGregor A; Zhang AD; Wallach JD; Ross JS; Herder M JAMA Netw Open; 2020 Jul; 3(7):e209498. PubMed ID: 32706379 [TBL] [Abstract][Full Text] [Related]
4. The right to a trial: Should dying patients have access to experimental drugs? Groopman J New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539 [No Abstract] [Full Text] [Related]
5. They are from the government and they really are here to help you. Woosley RL J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889 [No Abstract] [Full Text] [Related]
6. Evaluation of similar biotherapeutic products: scientific and regulatory challenges. Griffiths E; Thorpe R; Wadhwa M; Sohn Y Biologicals; 2011 Sep; 39(5):249. PubMed ID: 21925898 [No Abstract] [Full Text] [Related]
7. Communicating with the FDA: the "third rail" of a new model for drug development. Stanski DR; Orloff JJ J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890 [No Abstract] [Full Text] [Related]
8. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
9. Mutual recognition agreements and harmonization. Horton L Seton Hall Law Rev; 1998; 29(2):692-735. PubMed ID: 10569828 [No Abstract] [Full Text] [Related]
10. The FDA--a misunderstood agency. Sharfstein JM JAMA; 2011 Sep; 306(11):1250-1. PubMed ID: 21934058 [No Abstract] [Full Text] [Related]
11. Regulatory concerns at various phases of drug development. Aurecchia S; Orloff D; Sobel S Am J Cardiol; 1998 Apr; 81(8A):2F-4F. PubMed ID: 9604895 [No Abstract] [Full Text] [Related]
14. The importance and challenges of "mutual recognition". Merrill RA Seton Hall Law Rev; 1998; 29(2):736-55. PubMed ID: 10569829 [No Abstract] [Full Text] [Related]
15. An Indian manufacturer's perspective for harmonization of guidelines for similar biotherapeutic products. Babu PV Biologicals; 2011 Sep; 39(5):300-3. PubMed ID: 21816621 [TBL] [Abstract][Full Text] [Related]
16. Industry perspectives on ICH guidelines. Rockhold FW Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111 [TBL] [Abstract][Full Text] [Related]
17. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION. Effingham AM Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613 [No Abstract] [Full Text] [Related]
19. The use of the noninferiority analysis in clinical studies. Bermingham EC; del Castillo JR; Radecki SV Equine Vet J; 2014 Jul; 46(4):399-401. PubMed ID: 24909652 [No Abstract] [Full Text] [Related]
20. Current and future state of FDA-CMS parallel reviews. Messner DA; Tunis SR Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]